LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Company Announcement no. 21/2007

To: OMX Nordic Exchange			  Hørsholm, Denmark, September 7, 2007

LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a) 

Summary: Report of transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and
persons/companies closely associated with these. 

Hørsholm, Denmark, September 7, 2007; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX:LCP) is required, on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and
persons/companies closely associated with these. 

Name	Thomas Dyrberg
Reason for reporting	Member of the Board of Directors
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060048148
Type of transaction	Purchase of shares
Date of transaction	September 6, 2007
Relevant market 	         OMX, Nordic Exchange
Number of traded securities	3,800
Market value	         DKK 193,800

About LifeCycle Pharma A/S ("LCP A/S"): 
LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty
pharmaceutical company focused on developing and commercializing a portfolio of
innovative products in therapeutic areas such as cholesterol management,
hypertension, organ transplantation and autoimmune diseases. LCP's proprietary
MeltDose® technology, offers lower dosing, reduced side effects, improved
safety and patient compliance, and reduced product development costs and times.
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and
hypertriglyceridemia, is LCP's first FDA approved product (approved in August
2007). LCP is listed on the OMX Nordic Exchange under the trading symbol
(OMX:LCP). For further information, please visit www.lcpharma.com. 


Contact:

Michael Wolff Jensen
Executive Vice President and CFO
Tel. +45 70 33 33 00
Mob. +45 40 74 62 44
Email. mwj@lcpharma.com
---oo0oo---